As the public, doctors and governments react against the increasing cost of branded drugs, unilateral price-slashing could transform the industry, Bernard Munos writes. He points to international decisions that lower prices and reduce patent protections, as well as an article protesting the cost of new cancer medications as signs of dissatisfaction with the status quo.

Full Story:

Related Summaries